AMICUS THERAPEUTICS, INC.: total liabilities
Total liabilities for AMICUS THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All AMICUS THERAPEUTICS, INC. financial histories
What this measure means
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
Exact concept: us-gaap:Liabilities. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 675,629,000 | USD | 2026-02-20 | 10-K · 0001178879-26-000005 |
| At date | 2024-12-31 | 590,988,000 | USD | 2026-02-20 | 10-K · 0001178879-26-000005 |
| At date | 2023-12-31 | 617,706,000 | USD | 2025-02-19 | 10-K · 0001178879-25-000003 |
| At date | 2022-12-31 | 601,120,000 | USD | 2024-02-28 | 10-K · 0001178879-24-000003 |
| At date | 2021-12-31 | 597,771,000 | USD | 2023-03-01 | 10-K · 0001178879-23-000004 |
| At date | 2020-12-31 | 600,140,000 | USD | 2022-02-24 | 10-K · 0001178879-22-000006 |
| At date | 2019-12-31 | 373,782,000 | USD | 2021-03-01 | 10-K · 0001178879-21-000004 |
| At date | 2018-12-31 | 447,039,000 | USD | 2020-03-02 | 10-K · 0001178879-20-000015 |
| At date | 2017-12-31 | 274,174,000 | USD | 2019-02-28 | 10-K · 0001178879-19-000024 |
Related financial histories
- AMICUS THERAPEUTICS, INC.: total assets
- AMICUS THERAPEUTICS, INC.: stockholders equity
- AMICUS THERAPEUTICS, INC.: cash and cash equivalents
- AMICUS THERAPEUTICS, INC.: net income or loss
- AMICUS THERAPEUTICS, INC.: operating cash flow
- AMICUS THERAPEUTICS, INC.: capital expenditure payments
- AMICUS THERAPEUTICS, INC.: contract revenue excluding tax
- AMICUS THERAPEUTICS, INC.: financing cash flow
- AMICUS THERAPEUTICS, INC.: investing cash flow
- AMICUS THERAPEUTICS, INC.: retained earnings or deficit
- AMICUS THERAPEUTICS, INC.: basic weighted-average shares
- AMICUS THERAPEUTICS, INC.: diluted weighted-average shares
- AMICUS THERAPEUTICS, INC.: basic earnings per share
- AMICUS THERAPEUTICS, INC.: diluted earnings per share
- AMICUS THERAPEUTICS, INC.: income tax expense or benefit
- AMICUS THERAPEUTICS, INC.: net property, plant and equipment
- AMICUS THERAPEUTICS, INC.: share-based compensation expense
- AMICUS THERAPEUTICS, INC.: operating income or loss
- AMICUS THERAPEUTICS, INC.: current assets
- AMICUS THERAPEUTICS, INC.: interest expense
- AMICUS THERAPEUTICS, INC.: current liabilities
- AMICUS THERAPEUTICS, INC.: current accounts payable
- AMICUS THERAPEUTICS, INC.: goodwill carrying amount
- AMICUS THERAPEUTICS, INC.: net current accounts receivable
- AMICUS THERAPEUTICS, INC.: operating expenses
- AMICUS THERAPEUTICS, INC.: net inventory
- AMICUS THERAPEUTICS, INC.: gross profit
- AMICUS THERAPEUTICS, INC.: selling, general and administrative expense
- AMICUS THERAPEUTICS, INC.: common shares outstanding
- AMICUS THERAPEUTICS, INC.: cash including restricted cash
- AMICUS THERAPEUTICS, INC.: accumulated other comprehensive income or loss
- AMICUS THERAPEUTICS, INC.: operating lease right-of-use asset
- AMICUS THERAPEUTICS, INC.: operating lease liability
- AMICUS THERAPEUTICS, INC.: long-term debt
- AMICUS THERAPEUTICS, INC.: gross property, plant and equipment
- AMICUS THERAPEUTICS, INC.: accumulated depreciation on property, plant and equipment
- AMICUS THERAPEUTICS, INC.: net intangible assets excluding goodwill
- AMICUS THERAPEUTICS, INC.: other noncurrent assets
- AMICUS THERAPEUTICS, INC.: other noncurrent liabilities
- AMICUS THERAPEUTICS, INC.: prepaid expenses and other current assets
- AMICUS THERAPEUTICS, INC.: current contract liabilities
- AMICUS THERAPEUTICS, INC.: net deferred tax liabilities
- AMICUS THERAPEUTICS, INC.: pre-tax income or loss from continuing operations
- AMICUS THERAPEUTICS, INC.: profit or loss including noncontrolling interests
- AMICUS THERAPEUTICS, INC.: comprehensive income or loss
- AMICUS THERAPEUTICS, INC.: net income available to common stockholders
- AMICUS THERAPEUTICS, INC.: general and administrative expense
- AMICUS THERAPEUTICS, INC.: depreciation expense
- AMICUS THERAPEUTICS, INC.: depreciation, depletion and amortization
- AMICUS THERAPEUTICS, INC.: amortization of intangible assets
- AMICUS THERAPEUTICS, INC.: nonoperating interest expense
- AMICUS THERAPEUTICS, INC.: other nonoperating income or expense
- AMICUS THERAPEUTICS, INC.: deferred income tax expense or benefit
- AMICUS THERAPEUTICS, INC.: interest paid, net
- AMICUS THERAPEUTICS, INC.: income taxes paid, net
- AMICUS THERAPEUTICS, INC.: proceeds from issuing common stock
- AMICUS THERAPEUTICS, INC.: operating lease payments
- AMICUS THERAPEUTICS, INC.: change in accounts receivable
- AMICUS THERAPEUTICS, INC.: change in inventories
Inspect the source
- Entity
- AMICUS THERAPEUTICS, INC. / CIK 0001178879
- Captured
- 2026-09-21T17:18:57.135Z
- SEC response SHA-256
73914e72d339d9cea64a8df10ade02946e87028206ee72cc8fe363908f63ef32
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001178879.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))